Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Anne- Marie Malfait MD, PhD

Professor of Internal Medicine, Rush University Medical Center, Chicago

MalfaitAnne-Marie Malfait, MD (Ghent University, Belgium, 1989), PhD (Ghent University, 1994), is Professor of Internal Medicine, Division of Rheumatology, at Rush University Medical School, Chicago IL. She has a longstanding interest in cartilage biology and osteoarthritis, and more than 20 years of expertise with animal models of arthritis. Her postdoctoral fellowship at the Kennedy Institute of Rheumatology in London focused on cytokine regulation in experimental models of rheumatoid arthritis. From 2001-2009, she was Senior Principal Investigator at Pfizer and project leader of a drug-discovery team for development of disease-modifying osteoarthritis drugs (DMOADs). Pain in osteoarthritis is the focus of her research group at Rush University, where she established a multidisciplinary group that focuses on the mechanisms and neurobiology of joint pain. Dr. Malfait is an Associate Editor for Arthritis and Rheumatology and for Osteoarthritis and Cartilage, serves on the Board of Directors of OARSI, and is a member of the planning committees for the annual meetings of the American College of Rheumatology and Eular.

William Robinson MD, PhD

Associate Professor, Division of Immunology and Rheumatology, Stanford University

Robinson

 Dr. Robinson's research focuses on elucidation of the mechanisms underlying rheumatic diseases, including rheumatoid arthritis and osteoarthritis. The major objective of Dr. Robinson's laboratory is translational bench-to-bedside research, with the goal of rapidly converting discoveries at the bench into practical patient care tools and therapies. Dr. Robinson founded the Stanford Human Immune Monitoring Center, serves on the editorial boards of several major journals, and is an elected member of the American Society of Clinical Investigation.

 

 

 Frank P. Luyten MD, PhD

Professor of Rheumatology, KU Leuven

LuytenFrank P. Luyten is Chairman of the Division of Rheumatology at the University Hospitals Leuven, and full Professor at the KU Leuven, Belgium, Director of the Skeletal Biology and Engineering Research Center, and Director of Prometheus, an interdisciplinary platform at LR&D, KU Leuven.

Research expertise: Skeletal Biology and Pathology: Discovery of novel molecular partners in both BMP and Wnt signalling pathways and their role in skeletal and joint biology and arthritic diseases. Expert in regenerative medicine & tissue engineering supported by contributions in the field of cell based therapeutics for the regeneration of skeletal tissues. Clinical expertise mostly in the field of joint surface repair, osteoarthritis and osteoporosis.

Prof. Luyten is co-founder of Tigenix (2000), obtained the first central approval for a cell based ATMP at EMA in Europe and the company went public in 2009.

Carl Johan Sundberg PhD

Professor of Physiology, Karolinska Institute

SundbergCarl Johan Sundberg is a Licensed Physician and Professor of Physiology at the Department of Physiology and Pharmacology. He is also Chair of the Department of Learning, Informatics, Management and Ethics at KI. His research interests are focused on the molecular mechanisms that regulate the adaptation to exercise training. He is an elected member of the Royal Swedish Academy of Engineering Sciences and has served as member or chairman of numerous academic and industry boards, for example, as the Chairman of Research! Sweden – an independent advocacy foundation for medical research. He is also a board member of several biotechnology companies. He has received a Certificate of Commendation for Communication in the Life Sciences from EMBO and the European Commission's Descartes Communication Prize for Excellence in Science Communication in 2005.

Gordon Duff MA PhD MD FRCP FFPM FRCPE FMedSci FRSE

Principal, St Hilda's College, Oxford

DuffProfessor Sir Gordon Duff studied Medicine at Oxford and St Thomas's Hospital, London, where he also gained a PhD in Neuropharmacology. Following postgraduate medical training, he held junior faculty posts at Yale Medical School and the Howard Hughes Institute of Molecular Immunology. He joined Edinburgh Medical School in 1984, and in 1990 became Florey Professor of Molecular Medicine at Sheffield where he was also Faculty Research Dean and Director of the Division of Genomic Medicine. For two years, Sir Gordon was Chair of the UK's Medicines and Healthcare products Regulatory Agency before taking up his post as Principal of St Hilda's College in University of Oxford.

Sir Gordon was founding editor of the international research journal CYTOKINE, advisory editor to the Human Genome Organisation (HUGO) journal, and is Past-President of the International Cytokine Society. He was Knighted for services to Public Health in 2007, and listed in the 'Top 100' working scientists in the UK Science Council's list for 2014.

Ele Zeggini PhD

Group Leader, Wellcome Trust Sanger Institute, Cambridge

ZegginiEle obtained a BSc in Biochemistry from the University of Manchester Institute of Science and Technology (UMIST) in 1999 and a PhD in Immunogenetics of Juvenile Arthritis from the arc Epidemiology Unit, University of Manchester, in 2003. She then undertook a brief statistical genetics post doc focusing on rheumatic disorders, at the Centre for Integrated Genomic and Medical Research, University of Manchester, before moving to the Wellcome Trust Centre for Human Genetics, University of Oxford, to work on the genetics of type 2 diabetes. In 2006, Ele was awarded a Wellcome Trust Research Career Development Fellowship to examine design, analysis and interpretation issues in large-scale association studies. She joined the Wellcome Trust Sanger Institute Faculty in November 2008 and leads the Analytical Genomics of Complex Traits group. Ele's scientific interests focus on the genetics and genomics of complex traits, primarily cardiometabolic and musculoskeletal phenotypes, and on addressing relevant statistical genetics issues.

Nigel Arden MBBS, FRCP, MSc, MD

Professor of Rheumatic Diseases, Oxford

ArdenNigel Arden is a Professor of Rheumatic Diseases and an International Leader in epidemiology and predictive modelling and trial design. He has clinical and research expertise in osteoarthritis, arthroplasty and osteoporosis and has published numerous manuscripts based on the use of cohort and large routinely collected databases in musculoskeletal diseases and their treatment. His research interests focus on the epidemiology of musculoskeletal diseases, with a focus on Osteoarthritis and Osteoporosis; which has several major strands: (a) The risk factors of Osteoarthritis, Osteoporosis and lower limb Arthroplasty; (b) Clinical trials in the management of common musculoskeletal conditions; (c) personalised medicine in the treatment of musculoskeletal disease and (d) The role of sport and physical activity in health, especially musculoskeletal health.

Tim Hardingham PhD

Emeritus Professor

Tim HardinghamTim Hardingham is Emeritus Professor in the Wellcome Trust Centre for Cell-Matrix Research (www.wellcome-matrix.org), Faculty of Biology, Medicine and Health, University of Manchester, UK

Professor Hardingham was previously Professor of Biochemistry and the founding Director of the UK Centre for Tissue Engineering (2001-7), University of Manchester. He was formerly the Head of Biochemistry at the Kennedy Institute of Rheumatology in London (1984-94). He is a past member of the Molecular and Cellular Medicine Board of the Medical Research Council (UK) and also past Chairman of the Arthritis Research–UK Research Grants Committee (2006-10), a member of the NC3Rs grants panel (2010-2016) and Chairman of the British Society for Matrix Biology (BSMB). He has awards and honours, including the Colworth Medal of The Biochemical Society (1978), the Roussel International Award for Basic Research in Osteoarthritis (1989), the Carol Nachman International Prize for Research in Rheumatology (1991) and the Fell-Muir Award of the BSMB (2010). Professor Hardingham has been a member of ad hoc NIH study sections on Tissue Engineering and Bioengineering Research Partnerships (1999-2003) and served on the NASA/ESA research panel 2015.

He is a member of the Scientific Advisory Board of the Centre for Integrated Research into Musculoskeletal Ageing (CIMA, Liverpool, Newcastle, Sheffield), and on the International Advisory Board for the AR-UK Centre for Biomechanics and Bioengineering in Osteoarthritis (Cardiff) and formerly on the Advisory Board of Systems Biology Ireland (University College, Dublin) (2012-2015).

Professor Hardingham’s research interests are in the biology and pathology of cartilage and musculoskeletal tissues and the degenerative processes in osteoarthritis and other joint diseases. He also has long standing research interests in the physical properties and biological functions of extracellular matrices. Current research is focussed on the stratification of osteoarthritis using systems biology analysis of patients’ cartilage chondrocyte transcriptome. He also works with Prof Sue Kimber on the biology of chondrocytes and the differentiation of human embryonic stem cells and iPS cells to generate new strategies for cartilage repair.